• IE interfaces
• /
• v.16 no.4
• /
• pp.463-472
• /
• 2003

In this study we consider the problem of MPS(master production planning) of TFT-LCD(Thin Film Transistor - Liquid Crystal Display) production factory. Due to the complexities of the TFT-LCD production processes, it is difficult to build effective MPS. This study presents an algorithm having a concept of IDPQ(Ideal Daily Production Quantity) that considers line balancing of TFT-LCD production process. In general, the MPS building procedure does not consider line balancing in non-bottleneck processes. MPS without considering line balancing may make ineffective schedule. We present algorithms for building MPS considering factory capacity and line balancing according to the sales order.

• Journal of mucopolysaccharidosis and rare diseases
• /
• v.4 no.2
• /
• pp.37-41
• /
• 2018

Mucopolysaccharidosis III (MPS III, Sanfilippo syndrome) is a rare autosomal recessive disease caused by a deficiency of one of four enzymes involved in the degradation of glycosaminoglycan (GAG). The resultant cellular accumulation of GAG causes various clinical manifestations. MPS III is divided into four subtypes depending on the deficient enzyme. All the subtypes show similar clinical features and are characterized by progressive degeneration of the central nervous system. A number of genetic and biochemical diagnostic methods have been developed. However, there is no effective therapy available for any form of MPS III, with treatment currently limited to clinical management of neurological symptoms. Main purpose of the treatment for MPS III is to prevent neurologic deterioration. Because conventional intravenous enzyme replacement therapy (ERT) has a limitation due to inability to cross the blood-brain barrier, several innovative therapeutic approaches for MPS III are being developed. This review covers the currently developing new therapeutic options for MPS III including high dose ERT, substrate reduction therapy, intrathecal or intraventricular ERT, fusion protein delivery using bioengineering technology, and gene therapy.

• ETRI Journal
• /
• v.8 no.4
• /
• pp.133-143
• /
• 1986

본 연구에서는 새로운 서비스 / 상품에 대한 수요예측을 좀더 쉽고, 가능한 합리적으로 수행할 수 있게 하기위하여 개발된 MPS-NS개발의 기본배경, MPS-NS의 구성과 예측 알고리즘 등을 중심으로 소개하였다. MPS-NS는 표본조사를 통한 설문조사 방법을 새로운 서비스 / 상품의 수요예측에 적용할 수 있도록 만들어진 새로운 서비스 시장 침투 분석S/W이다.

• Journal of mucopolysaccharidosis and rare diseases
• /
• v.3 no.1
• /
• pp.14-19
• /
• 2017

Lysosomal storage diseases (LSDs) are a group of rare inherited metabolic disorders caused by the deficiency of specific lysosomal enzymes and subsequent accumulation of substrates. Enzyme deficiency leads to progressive intra-lysosomal accumulation of the incompletely degraded substances, which cause dysfunction and destruction of the cell and eventually multiple organ damage. Patients have a broad spectrum of clinical phenotypes which are generally not specific for some LSDs, leading to missed or delayed diagnosis. Due to the availability of treatment including enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation for some LSDs, early diagnosis is important. ERT products have been approved with optimal outcomes for some LSDs in the recent decades, including Gaucher, Fabry, mucopolysaccharidosis (MPS) I, Pompe, MPS VI, MPS II, and MPS IVA diseases. ERT can stabilize the clinical condition, prevent disease progression, and improve the long-term outcome of these diseases, especially if started prior to irreversible organ damage. Based on the availability of therapy and suitable screening methods in the recent years, some LSDs, including Pompe, Fabry, Gaucher, MPS I, MPS II, and MPS VI diseases have been incorporated into nationwide newborn screening panels in Taiwan.

• Journal of Korean Society of Water and Wastewater
• /
• v.32 no.4
• /
• pp.337-348
• /
• 2018

As the issue of microplastics (MPs) detection in tap water was raised in other countries in 2017, monitoring of MPs in drinking and source water, and sewage treatment plant (STP) effluents was initiated. This study intends to look into other studies on MPs in STPs at home and abroad, and review the characteristics of MPs and their removal efficiencies in the STPs, the risk and effect of MPs on watersheds, and management practices in order to help better understand MPs in STPs. To manage MPs effectively in STPs, it is necessary to investigate the detection of MPs discharged from STPs, do research on human health risk and control measures, and build a monitoring system including standardized analytical methods.

• Journal of Yeungnam Medical Science
• /
• v.41 no.3
• /
• pp.179-187
• /
• 2024

Myofascial pain syndrome (MPS) is a common musculoskeletal disorder characterized by muscle pain, tenderness, and trigger points. Ultrasonography has emerged as a key tool for diagnosing and treating MPS owing to its ability to provide precise, minimally invasive guidance. This review discusses the use of ultrasonography in various approaches to evaluate and manage MPS. Studies have shown that shear-wave sonoelastography can effectively assess muscle elasticity and offer insights into trapezius stiffness in patients with MPS. Ultrasound-guided interfascial hydrodissection, especially with visual feedback, has demonstrated effectiveness in treating trapezius MPS. Similarly, ultrasound-guided rhomboid interfascial plane blocks and perimysium dissection for posterior shoulder MPS have significantly reduced pain and improved quality of life. The combination of extracorporeal shockwave therapy with ultrasound-guided lidocaine injections has been particularly successful in reducing pain and stiffness in trapezius MPS. Research regarding various guided injections, including dry needling, interfascial plane blocks, and fascial hydrodissection, emphasizes the importance of ultrasonography for accuracy and safety. Additionally, ultrasound-guided delivery of local anesthetics and steroids to the quadratus lumborum muscle has shown lasting pain relief over a 6-month period. Overall, these findings highlight the pivotal role of ultrasonography in the assessment and treatment of MPS.

• KSCE Journal of Civil and Environmental Engineering Research
• /
• v.41 no.1
• /
• pp.13-20
• /
• 2021

Recently, various piloti structures have been constructed in Korea to secure residential and parking spaces. However, these piloti structures have been constructed in the form of protruding columns without walls to secure parking spaces on the first floor. In this form, when an earthquake occurs, the column is relatively easily damaged compared to general structures, and such damage can lead to the collapse of the structure. Therefore, in this study, a study on securing the safety of the piloti structure using the MPS (Multi Performance System) seismic isolation device was conducted. Nonlinear dynamic analysis according to the presence or absence of MPS seismic isolation device was performed on the existing piloti structure, and analysis results were compared and analyzed. Finally, each seismic performance evaluation was performed and the superiority of the MPS seismic isolation device was verified.

• Journal of Korea Multimedia Society
• /
• v.22 no.7
• /
• pp.815-821
• /
• 2019

This paper presents the design and implementation of a Mission Planning System(MPS) for multiple ballistic missiles. MPSs are also a kind of M&S systems in defense domain, and these provide important computations on the ground before flights of flying objects. The proposed MPS in this paper has a new concept which is far from generating a set of waypoints of a flying object and proving the set. In this paper, we firstly discuss the research motivation of our own MPS; then, we introduce the design of our MPS and its functionalities. In order to prove the practicality of our MPS, we have conducted a case study.

• Journal of mucopolysaccharidosis and rare diseases
• /
• v.5 no.1
• /
• pp.22-28
• /
• 2021

Mucopolysaccharidosis type III (MPS III) or Sanfilippo disease is an orphan-inherited lysosomal storage disease. It is one of the most common MPS subtypes. The classical presentation is an infantile-onset neurodegenerative disease characterized by intellectual regression, behavioral and sleep disturbances, loss of ambulation, and early death. Unlike other MPS, no disease-modifying therapy has been approved. Here, we review the curative therapy developed for MPS III, from historically ineffective hematopoietic stem cell transplantation and substrate reduction therapy to the promising enzyme replacement therapy or adeno-associated/lentiviral vector-mediated gene therapy. Preclinical studies are presented with recent translational first-in-man trials. We also present experimental research with preclinical mRNA and gene-editing strategies. Lessons from animal studies and clinical trials have highlighted the importance of early therapy before extensive neuronal loss. Disease-modifying therapy for MPS III will likely mandate the development of new early diagnosis strategies.

• Journal of mucopolysaccharidosis and rare diseases
• /
• v.5 no.1
• /
• pp.12-16
• /
• 2021

Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is an X-linked lysosomal storage disorder caused by deficiency of the enzyme iduronate-2-sulfatase, leading to the accumulation of glycosaminoglycans (GAGs), which affects multiple organs and systems. Current treatments for MPS II include enzyme replacement therapy (ERT) and hematopoietic cell transplantation (HCT) to reduce the accumulation of GAGs. HCT has the potential advantage that donor-derived enzyme-competent cells can provide a continuous secreting source of the enzyme. However, HCT as a treatment for MPS II remains controversial because its effectiveness is unclear, particularly in terms of neurological symptoms. To date, several clinical experiences with HCT in MPS II have been reported. In this paper, we review post-HCT outcomes in the previously published literature and discuss the effects of HCT on each of the clinical signs and symptoms of MPS II.